, /PRNewswire/ - Optimi Health Corp. (CSE: OPTI) (OTCQX: ) (FRA: 8BN), a leading Health Canada-licensed GMP psychedelics pharmaceutical manufacturer specializing in controlled substances such as botanical psilocybin and MDMA, is pleased to announce it has closed a third and final tranche of its non-brokered private placement (the " "). The Offering consisted of units (each a " ") at per Unit for gross proceeds of .
Optimi raised in the third tranche closed , in the second tranche closed , and in the first tranche which closed . Each Unit under the Offering is comprised of 1 common share in the capital of the Company (each a " ") and 1/2 of a transferable Common Share purchase warrant (each whole warrant a " "). Each Warrant entitles the holder to acquire 1 Common Share at for 2 years from the date of issuance, subject to an accelerated expiry provision, whereby in the event the closing price of the Company's Common Shares on the Canadian Securities Exchange (the " ") exceeds for a period of 20 consecutive trading days, at the Company's election, the period within which the Warrants are exercisable, will be reduced and the holders of the Warrants will be entitled to exercise their Warrants for a period of 30 days commencing on the day the Company provides notice, any outstanding Warrants not exercised during the 30 day period will expire.
The Company intends to use the net proceeds from the Offering to obtain its Drug Establishment License, facilitate commercialization, and fo.
